of PKC in the novel synergistic action of urotensin II and angiotensin II and in urotensin II-induced vasoconstriction. Am J Physiol Heart Circ Physiol 292: H348 -H359, 2007. First published September 1, 2006; doi:10.1152/ajpheart.00512.2006.-The intracellular signaling of human urotensin II (hU-II) and its interaction with other vasoconstrictors such as ANG II are poorly understood. In endothelium-denuded rat aorta, coadministration of hU-II (1 nM) and ANG II (2 nM) exerted a significant contractile effect that was associated with increased protein kinase C (PKC) activity and phosphorylation of PKC-␣/␤II and myosin light chain, whereas either hU-II or ANG II administered alone at these concentrations had no statistically significant effect. This synergistic effect was abrogated by the PKC inhibitor chelerythrine (10 and 30 M), the selective PKC-␣/␤II inhibitor Gö-6976 (0.1 and 1 M), the hU-II receptor ligand urantide (30 nM and 1 M), or the ANG II antagonist losartan (1 M). Moreover, in endotheliumintact rat aorta, the synergistic effect of hU-II and ANG II was not exerted any longer, and this synergistic effect was unmasked by pretreatment of the nitric oxide synthase inhibitor N G -nitro-L-arginine methyl ester. hU-II (10 nM) alone caused a long-lasting increase in phospho-PKC-, phospho-myosin light chain, and PKC activity, which was associated with long-lasting vasoconstriction. These changes were prevented by chelerythrine. Methoxyverapamil-thapsigargin treatment reduced the hU-II-induced vasoconstriction by ϳ50%. The methoxyverapamil-thapsigargin-resistant component of hU-II-induced vasoconstriction was dose-dependently inhibited by chelerythrine. In conclusion, hU-II induces a novel PKC-dependent synergistic action with ANG II in inducing vasoconstriction. PKC-␣/ ␤II is probably the PKC isoform involved in this synergistic action. Nitric oxide produced in the endothelium probably masks this synergistic action. The long-lasting vasoconstriction induced by hU-II alone is PKC dependent and associated with PKC-phosphorylation.
cord), human kidney epithelial cells (27, 39) , rat pancreas (40) , and human urine (28) . UT receptors were identified in cardiomyocytes (17) , vascular smooth muscle cells (VSMCs) (1) , endothelial cells (1) , spinal cord (10) , and endocrine tissue (9) .
Moreover, the linkage between U-II and cardiovascular diseases has been suggested by several experimental and clinical studies. U-II stimulation increased the level of procollagens and fibronectin mRNA transcripts in neonatal cardiac fibroblasts (17) . The expression of U-II has been shown to be upregulated in the myocardium (13) and plasma (36) of patients with congestive heart failure, as well as in infarcted heart of the rat (43) , the plasma of hypertensive patients (8) , and atherosclerotic lesions of human aorta (4) . However, a few independent groups did not observe positive correlation between plasma U-II levels and congestive heart failure (14, 21) . To date, the implied role of U-II in disease states is postulated largely on the basis of changes in the expression levels of this peptide (and/or its receptor) in the disease processes.
U-II has been shown to effectively contract the isolated arteries from rats (15) , rabbits (12) , dogs (12) , pigs (12) , nonhuman primates (1) , and humans (26) . On the other hand, the reported depressor and regionally selective vasodilator effects (3, 12, 26, 48) of U-II endow its vasoactive effects with complexity. Interestingly, exogenously administered U-II induced a vasoconstrictor response in skin microvasculature in patients with chronic heart failure (25) and essential hypertension (41) , in contrast to its vasodilator effects in normal subjects, suggesting differential roles of U-II in cardiovascular physiology and pathophysiology. In cardiovascular diseases, the expression of many vasoconstrictors such as ANG II (34) , endothelin (2) , catecholamines (44) , thromboxane A 2 (29) , and serotonin (23) has been shown to be upregulated. These studies give rise to the hypothesis that the interaction between U-II and other vasoactive substances may be crucial in modulating the vasoactive effect of U-II under a certain disease status.
Cross talk of intracellular signaling pathways is probably the underlying mechanism of the interaction between U-II and other vasoactive substances (48) . Nevertheless, the intracellular signaling of U-II remains largely unknown. In isolated rabbit thoracic aorta, the contractile effect of human U-II (hU-II) was significantly inhibited by 2-nitro-4-carboxyphenyl-N,N,-diphenylcarbamate, a phospholipase C inhibitor, but not by indomethacin, a cyclooxygenase inhibitor. Meanwhile, hU-II increased phosphoinositide hydrolysis, and this effect was also inhibited by the phospholipase C inhibitor, suggesting a role of the phospholipase C-dependent inositol phosphate pathway in mediating hU-II-induced vasoconstriction (37) . In isolated rat aortic rings, hU-II increased cytosolic Ca 2ϩ levels. Complete inhibition of the cytosolic Ca 2ϩ increase could only prevent a part of the hU-II-induced vasoconstriction. Likewise, protein kinase C (PKC) inhibitor Gö-6976, MEK inhibitor U-0126, p38 MAPK inhibitor SB-203580, and myosin light chain (MLC) kinase inhibitor wortmannin partially inhibited the U-II-induced vasoconstriction, suggesting the involvement of multiple signaling pathways (42) .
The present study aimed to investigate the purported interaction between hU-II and ANG II in inducing the contraction of arterial vascular smooth muscles, as well as the intracellular signaling of hU-II in the presence or absence of ANG II. (44) and equilibrated for 1 h at 37°C under a resting tension of 2 g before all subsequent manipulations. In concentration-response studies, hU-II or ANG II (1 pM to 1 M) was administered at 5-min intervals. To block the vasoconstrictor effect of hU-II, urantide (30 nM and 1 M) or chelerythrine (30 M) (47) was administered 30 min in advance. To further elucidate the role of Ca 2ϩ in hU-II-induced vasoconstriction, the voltage-gated Ca 2ϩ channel inhibitor methoxyverapamil (20 M) (31) and Ca 2ϩ store-depleting agent thapsigargin (2 M) (32) were used to suppress the agonist-induced rise in intracellular Ca 2ϩ concentration ([Ca 2ϩ ]i). To block the vasoconstrictor effect of ANG II, losartan (1 M) (19) was administered 30 min in advance. To assess the synergistic action of hU-II and ANG II, hU-II (1 nM) was administered 20 min before ANG II (2 nM) administration. To investigate the mechanisms of the synergistic action of hU-II and ANG II, losartan (1 M) (19) , urantide (30 nM and 1 M), chelerythrine (10 and 30 M) (47), or Gö-6976 (0.1 and 1 M) (24) was administered 30 min before hU-II administration. Additional experiments were performed to examine the effect of a mechanical increase in resting tension on the contractile response to 2 nM ANG II using phenylephrine (0.1 M) to induce a similar increase in resting tension, which was induced by 1 nM hU-II. Responses were normalized to that induced by 100 mM KCl.
MATERIALS AND METHODS

Measurement of vasoconstriction.
For Western blot analysis, the aortic rings were quickly removed from the organ bath, snapped in liquid nitrogen, and homogenized in SDS sample buffer containing 0.05 mol/l Tris⅐HCl, 2% SDS, 10% glycerol, and proteinase inhibitor cocktail (Roche, Mannheim, Germany).
Cell culture. Aortic VSMCs of the rat were obtained from the American Type Culture Collection (no. CRL-2018, SV402T-SMC clone HEP-SA). Human VSMCs were isolated from umbilical arteries as previously described (5) and identified by immunocytochemical staining with ␣-smooth muscle actin antibodies (Santa Cruz Biotechnology, Santa Cruz, CA). The cells were incubated in DMEM supplemented with 10% FBS and antibiotics (100 U/ml penicillin, 100 g/ml streptomycin) in a humidified atmosphere of 95% air-5% CO2 at 37°C. Cells at ϳ80% confluence in culture wells were made quiescent by incubation with 0.4% FBS medium for 24 -48 h before treatment and were incubated for 0 -60 min with hU-II (100 nM). In some experiments, VSMCs were pretreated with various inhibitors for 30 min before hU-II treatment.
Measurement of [Ca 2ϩ ]i. For measurement of [Ca 2ϩ ]i in VSMCs, the cells were loaded with 2 mM fluo 3-AM at 37°C. Measurements were performed with an MRC 600 confocal imaging system and laser scanning confocal microscope (Radiance 2000; Bio-Rad, Hertfordshire, UK). Briefly, VSMCs were seeded onto glass coverslips and incubated with fluo 3-AM at 37°C under an atmosphere of 5% CO 2. After a loading period of 30 min, the cells were washed and placed on the stage of the microscope. The fluorescence in the cell was excited at 488 nm by an argon-ion laser, and emission at wavelengths between 515 and 545 nm was detected by a photomultiplier. Peak [Ca 2ϩ ]i was determined from the average of three data points.
Western blot analysis. Cells and tissue specimens were homogenized in SDS sample buffer (Roche). Protein was extracted from the homogenates, and protein content was determined in the lysate supernatant. Each sample (10 g) was separated by electrophoresis on a 7.5% or 15% polyacrylamide-SDS gel and transferred to polyvinylidene difluoride membrane (Gelman-Pall, Ann Arbor, MI). The membranes were incubated with the primary antibodies against various intracellular proteins. Antigen detection was performed with an ECL detection kit (Pierce, Rockford, IL). Phosphorylation of the PKC targets, i.e., (ser)PKC substrate and myristoylated alanine-rich protein kinase C substrate (MARCKS), was assessed as parameters of PKC activity by Western blot analysis. The following primary antibodies were used: anti-phospho-MLC (Ser 19 ), anti-phospho-(ser)PKC substrate, anti-phospho-PKC-␣/␤II (Thr To detect PKC activation and MLC phosphorylation involved in the synergistic action of hU-II and ANG II, hU-II (1 nM) was administered 20 min before ANG II (2 nM). Five minutes after ANG II administration, the aortic rings were quickly removed from the organ bath, snapped in liquid nitrogen, and homogenized for subsequent Western blot analysis.
Chemicals. hU-II was obtained from Bachem (Bubendorf, Switzerland). Chelerythrine, thapsigargin, methoxyverapamil, ANG II, N Gnitro-L-arginine methyl ester (L-NAME), and Gö-6976 were obtained from Sigma (St. Louis, MO). Losartan was provided by MSD (Whitehouse Station, NJ). Urantide was custom synthesized by GL Biochem (Shanghai, China). DMSO was from Wako (Richmond, VA). Fluo 3-AM was from Calbiochem (La Jolla, CA). Methoxyverapamil and chelerythrine were dissolved in DMSO. All cell culture reagents were obtained from Sigma.
Statistics. All values are expressed as means Ϯ SE, and n represents the number of samples of cell cultures or animals from which blood vessels were isolated. Statistical comparisons were performed by one-way ANOVA, followed by the Student-Newman-Keuls test. A P value of Ͻ0.05 was taken as statistically significant. greater contractile response in vessels pretreated with hU-II than vessels pretreated with vehicle ( Fig. 1, C and D ; n ϭ 6 in each group). The putative synergistic action of hU-II and ANG II was further studied at concentrations of 1 and 2 nM for hU-II and ANG II, respectively. At the above-mentioned respective concentrations for hU-II and ANG II, neither of these two peptides administered alone was effective in causing statistically significant contraction of the endothelium-denuded aorta compared with the vehicle-treated control, although a trend toward an increase in vascular tension was observed in vessels treated with hU-II alone (Fig. 1, E and F) . Interestingly, ANG II (2 nM) elicited a significantly increased constriction of the vessels pretreated with hU-II (1 nM) compared with either control or the vessels treated with ANG II alone (P Ͻ 0.05; Fig. 1, E and F) . Moreover, this synergistic action was prevented by the ANG II AT 1 -receptor antagonist losartan (1 M), the UT-receptor ligand urantide (30 nM and 1 M), the PKC inhibitor chelerythrine (10 and 30 M) or the selective PKC-␣/␤II inhibitor Gö-6976 (0.1 and 1 M) (Fig. 2) , suggesting a PKC-dependent cross talk between the intracellular signaling pathways mediated by the AT 1 receptor and UT receptor in arterial smooth muscle.
RESULTS
Synergistic action of hU-II and ANG II in contracting the
Because mechanical increases in the resting tension may influence the contractile response to ANG II, phenylephrine was employed to create a control group with increased resting tension. Phenylephrine (0.1 M) induced an increase in resting tension comparable with that induced by 1 nM hU-II but had no effect on the vasoactive effect of 2 nM ANG II, excluding the possibility that the synergistic interaction between hU-II and ANG II was simply induced by the hU-II-induced increase in resting tension.
Role of endothelium in the synergistic action of hU-II and ANG II. hU-II (1 nM) did not potentiate the vasoconstrictive effect of ANG II (2 nM) any longer in endothelium-intact aortic rings isolated from the Sprague-Dawley rat (Fig. 3) . Pretreatment with the nitric oxide synthase inhibitor L-NAME uncovered the synergistic action of hU-II and ANG II, suggesting a role of endothelial nitric oxide in masking the synergistic action of hU-II and ANG II (Fig. 3) . Synergistic action of hU-II and ANG II in inducing PKC activation and MLC phosphorylation. The synergism of hU-II and ANG II was also observed in their actions on the intracellular molecules PKC and MLC in endothelium-denuded aortic tissue of the Sprague-Dawley rat. Phosphorylation of the PKC targets, i.e., (ser)PKC substrate, was assessed as parameters of PKC activity. When administered alone, neither hU-II (1 nM) nor ANG II (2 nM) caused significant increase in PKC activity (Fig. 4A ) and MLC phosphorylation (Fig. 4B ) in endotheliumdenuded thoracic aorta. Coadministration of hU-II (1 nM) and ANG II (2 nM) produced an apparent increase in PKC activity (Fig. 4A ) and MLC phosphorylation (Fig. 4B) , indicating a synergistic action of hU-II and ANG II on the intracellular molecules PKC and MLC.
Synergistic action of hU-II and ANG II in selective phosphorylation of the PKC isoform ␣/␤II. To detect the PKC isoforms involved in the synergistic contractile effects of hU-II and ANG II, endothelium-denuded aortic tissues treated with a combination of hU-II (1 nM) and ANG II (2 nM) were quickly removed from the organ bath and snapped in liquid nitrogen when a significant contractile response was observed. Phosphorylation of PKC isoforms was detected by Western blot analysis with homogenates of the aortic tissues of the SpragueDawley rat. PKC-␣/␤II was selectively phosphorylated by combined treatment of hU-II (1 nM) and ANG II (2 nM) but not by hU-II (1 nM) or ANG II (2 nM) alone (Fig. 5, A and B) . On the other hand, hU-II administered alone at a higher concentration (10 nM) resulted in time-dependent (5, 15, and 30 min) selective phosphorylation of PKC isoforms ␣/␤II and (Fig. 5, C and D) . Worthy of notice is that the time course of hU-II (10 nM)-induced phosphorylation of PKC- (Fig. 5D) is associated with the long-lasting pattern of hU-II (10 nM)-induced vasoconstriction (Fig. 1B) . However, hU-II administered alone at a lower concentration (1 nM) had no significant effect on phosphorylation of the PKC isoforms at corresponding time points (Fig. 5, E and F) .
Phosphorylation of MLC in VSMCs and aortic tissues induced by hU-II.
Homogenates of cultured VSMCs or aortic tissues were analyzed by Western blot analysis. hU-II caused a dose-dependent increase in MLC phosphorylation in cultured aortic VSMCs of the Sprague-Dawley rat (Fig. 6A) . A single administration of hU-II (100 nM for cultured cells and 10 nM for aortic tissues) caused MLC phosphorylation for at least 30 min in cultured rat aortic (Fig. 6B ) and human umbilical (Fig.  6C ) VSMCs and in endothelium-denuded thoracic aorta of the Sprague-Dawley rat (Fig. 6D) . In cultured aortic VSMCs of the Sprague-Dawley rat, hU-II-induced MLC phosphorylation was prevented by urantide at concentrations of 30 and 300 nM but not at 3 nM (Fig. 6E) . In endothelium-denuded thoracic aorta of the Sprague-Dawley rat, hU-II-induced MLC phosphorylation was prevented by urantide at concentrations of 30 nM and 1 M (Fig. 6F) . These data suggested a role of MLC in mediating intracellular signaling after UT receptor stimulation.
hU-II activates PKC through UT receptors. A single administration of hU-II (100 nM for the cells and 10 nM for the tissues) caused time-dependent PKC activation in cultured rat aortic VSMCs (Fig. 7A ) and endothelium-denuded thoracic aorta of the Sprague-Dawley rat (Fig. 7B) . hU-II-induced PKC activation in aortic tissue was prevented by urantide (1 M) (Fig. 7C) , supporting a role for PKC in mediating the intracellular signaling on UT receptor stimulation.
PKC is required for hU-II-induced MLC phosphorylation and vasoconstriction. In cultured rat aortic VSMCs, the PKC inhibitor chelerythrine (1 M) was effective in abrogating hU-II (100 nM)-induced increase in PKC activity (Fig. 8A ) and MLC phosphorylation (Fig. 8B) . In endothelium-denuded thoracic aorta of the Sprague-Dawley rat, hU-II-induced MLC phosphorylation (Fig. 8C) and vasoconstriction (Fig. 8D) were also prevented by chelerythrine (30 M). The cumulative concentration-response curve of hU-II-induced vasoconstriction was shifted rightward in a parallel manner by 30 nM urantide, and the effect of hU-II was almost abolished by 1 M (Fig. 8D) . Losartan (1 M) had no effect on vasoconstriction induced by hU-II alone (Fig. 8D) . ANG II-induced vasoconstriction was inhibited by losartan (1 M) and chelerythrine (30 M) but not by urantide (1 M) (Fig. 8E) . These data suggest that PKC is an upstream regulator of MLC phosphorylation in hU-II-induced arterial smooth muscle contraction. PKC is also involved in vasoconstriction induced by ANG II alone.
Role of calcium in hU-II-induced vasoconstriction. hU-II (100 nM) caused a significant increase in [Ca 2ϩ ] i in rat aortic VSMCs as observed by confocal microscope (Fig. 9A) . Methoxyverapamil-thapsigargin treatment reduced the hU-IIinduced vasoconstriction by ϳ50% in endothelium-denuded thoracic aorta of the Sprague-Dawley rat. The methoxyverapamil-thapsigargin-resistant component of hU-II-induced vasoconstriction was dose-dependently inhibited by chelerythrine, with IC 50 value of 7.98 M (Fig. 9B ; n ϭ 6), suggesting Ca 2ϩ sensitization of the contractile apparatus through the activation of PKC.
DISCUSSION
The role of U-II in cardiovascular physiology and diseases remains largely uncertain. Recent experimental and clinical studies have revealed increased expression of U-II and UT receptor in animals with experimentally induced myocardial infarction and heart failure and in patients with hypertension, atherosclerosis, and diabetic nephropathy, suggesting a potential role of U-II in both cardiovascular and renal diseases (22) . On the other hand, numerous neurohumoral factors such as ANG II, endothelin, and catecholamines have been reported to be involved in these disease states (2, 30, 34) . Therefore, it is important to know the interaction between U-II and other vasoactive factors under physiological and pathological conditions.
The present study demonstrates a synergistic action of hU-II and ANG II in contracting arterial smooth muscle. This is the first demonstration of a synergistic effect of hU-II with ANG II in vasoconstriction. In line with the present study, the synergistic effect of hU-II with mildly oxidized LDL (45) and serotonin (46) on VSMC proliferation has been reported.
The intracellular signaling of U-II-induced vasoconstriction remains largely unknown. Most published studies in this area have been performed in isolated aortic rings with synthetic inhibitors to distinguish the pathways involved. In isolated rabbit thoracic aorta, the contractile effect of hU-II was reported to be mediated by a phospholipase C-dependent-inositol trisphosphate pathway (37) . In isolated rat aortic rings, Ca 2ϩ , PKC, ERK, MAPK, and MLC have been suggested to be involved in hU-II-induced vasoconstriction. The conclusion of this study (42) was based on the inhibitory effects of the synthetic inhibitors for the above-mentioned intracellular elements. Whether there was an activation of certain signaling elements, e.g., PKC, was not elucidated. Sauzeau et al. (38) reported an hU-II-induced RhoA activation. The RhoA inhibitor TAT-C3 and Rho-kinase inhibitor Y-27632 partially inhibited the hU-II-induced vasoconstriction (38) . Herein, we report a selective phosphorylation of PKC isoforms ␣/␤II and and increased PKC activity induced by hU-II (10 nM) alone in endothelium-denuded rat thoracic aorta. Interestingly, the time course of hU-II-induced phosphorylation of PKC-␣/␤II was rather transient (ϳ5 min), whereas the phosphorylation of PKC-was long lasting (ϳ30 min). Also, in rat aorta, Giebing et al. (16) recently suggested that the sustained contractile response to U-II is ascribed to the continuous externalization and recycle of UT receptors in VSMCs. Whether the longlasting phosphorylation of PKC-observed in the present study contributes to the long-lasting effect of hU-II-induced vasoconstriction remains to be elucidated.
On the other hand, the synergistic action of hU-II (1 nM) and ANG II (2 nM) observed in the present study was associated with a selective phosphorylation of PKC-␣/␤II. This synergistic effect on vasoconstriction was abrogated by either the PKC inhibitor chelerythrine, the selective PKC-␣/␤II inhibitor Gö-6976, the ANG II AT 1 -receptor antagonist losartan, or the UT-receptor ligand urantide. These data suggest that PKC mediates the cross talk of the intracellular signaling pathways triggered by the UT receptor and AT 1 receptor. Moreover, ␣/␤II is probably the PKC isoform involved in PKC-mediated cross talks of the signaling pathways of these two peptides.
Urantide has been used in the present study as a UT-receptor antagonist. This UT-receptor ligand has been shown to produce a concentration-related competitive inhibition of U-II-induced contraction in rat thoracic aorta (pK B ϭ 8.3) without any agonistic effect up to a concentration of 1 M (33). However, urantide has also been shown to act as a low-efficacy partial agonist in inducing Ca 2ϩ release in Chinese hamster ovary cells overexpressing human UT receptors (6, 7) . Although the efficacy of a UT-receptor ligand as a partial agonist may be overestimated in such a cell system expressing high levels of recombinant UT receptors, the partial agonistic effect of urantide suggests that this UT-receptor ligand is probably not the best tool to define receptor subtype.
PKC phosphorylation has been well established as an upstream regulator of MLC in inducing arterial smooth muscle contraction (18) . In the present study, the vasoconstriction induced by hU-II alone or the combination of hU-II and ANG II was coupled with an increase in PKC activity and MLC phosphorylation. Meanwhile, inhibition of PKC diminished hU-II-induced MLC phosphorylation in VSMCs, suggesting a role of PKC in mediating hU-II (alone or synergistically with ANG II)-induced smooth muscle contraction through phosphorylation of MLC.
Intracellular Ca
2ϩ has been shown to be involved in hU-IIinduced vasoconstriction (38, 42 sensitization of PKC-dependent contractile apparatus are involved in hU-II-induced vasoconstriction. On the other hand, PKC may also mediate hU-II-induced smooth muscle contraction through a pathway independent of a rise in [Ca 2ϩ ] i . In the present study, the synergistic effect of U-II and ANG II was not present any longer in endothelium-intact aortic rings. Interestingly, pretreatment with L-NAME uncovered this synergistic effect in endothelium-intact aortic rings, suggesting a role of nitric oxide in blunting the synergistic effect of U-II and ANG II. Worthy of notice is that endothelium dysfunction has been well established in cardiovascular diseases (20) ; therefore, the synergistic effect of U-II and ANG II may be unmasked in these disease states. In line with this hypothesis, iontophoresis-administered hU-II (0.001, 1, and 100 nM) induced a vasoconstrictor response in skin microvasculature as assessed by laser-Doppler velocimetry in patients with either chronic heart failure (25) or essential hypertension (34) , which is in sharp contrast to its vasodilator effect in normal subjects. The underlying mechanisms of the differential effects of hU-II on vascular tone in normal subjects and in patients with chronic heart failure and hypertension are interesting and remain to be clarified. It is possible, for example, that endothelium dysfunction, the diversity in the intracellular signaling pathways downstream of the UT receptor, and/or the interactions between hU-II and other vasoactive factors in disease states may modulate the vasoactive effect of hU-II (48) . The present study provides direct evidence for a synergistic action of hU-II and ANG II through a PKC-dependent cross talk of the intracellular signaling pathways of the UT receptors and ANG II AT 1 receptors. This synergistic action may amplify the vasoactive effects of hU-II and ANG II in diseases such as hypertension and heart failure. In support of this hypothesis, it has been demonstrated that plasma hU-II levels increased in patients with hypertension (8) . In heart failure patients, both positive (30, 35, 36) and negative (21) correlations between plasma hU-II levels and the disease have been reported. Moreover, ANG II levels have been shown to be increased in hypertension (34) and heart failure (34) . In patients with hypertension or heart failure, increased hU-II and ANG II may interact on each other and produce a stronger contractile effect than that produced by either of the peptides alone. In addition, endothelium dysfunction may uncover the interaction between hU-II and ANG II. On the other hand, the receptors of hU-II and ANG II on VSMCs may be upregulated in hypertension and heart failure (14, 43) and hence result in increased cross talks of the intracellular signaling pathways of these two peptides.
In conclusion, hU-II potentiates the vasoconstrictor effect of ANG II by a PKC-dependent cross talk of the intracellular signaling pathways of these two peptides. ␣/␤II is probably the PKC isoform involved in this synergism. Nitric oxide produced in the endothelium probably masks this synergistic action. The long-lasting vasoconstriction induced by hU-II alone is PKC dependent and associated with PKC-phosphorylation. PKC is an upstream regulator of MLC. [Ca 2ϩ ] i sensitizes PKC-dependent vasoconstriction induced by hU-II.
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